Sarah S.
- Country
- Germany
- Department
- Kinder- und Jugendklinik
Research Overview
- Evaluation of Etavopivat, a Pyruvate Kinase Activator, in a Randomized, Placebo-Controlled Study for Sickle Cell Disease in Patients Aged 12 to 65 Years
- Long-term Safety and Efficacy Evaluation of Etavopivat in Patients with Sickle Cell Disease or Thalassaemia Transitioning from Previous Etavopivat Studies
- Evaluation of Irinotecan, Ifosfamide, Vincristine, and Dactinomycin in Frontline and Relapsed Rhabdomyosarcoma in Pediatric and Adult Populations
Data & Insights
Has run more than one trial at 42 of 203 partner sites.
Specializations
Pediatric Oncology
The investigator specializes in treating Ewing sarcoma, focusing particularly on patients with GD2-positive variants of this rare bone cancer. Their research encompasses therapeutic approaches for pediatric, adolescent, and adult populations.
- Advanced Combination Therapy
- Bone Cancer Treatment
- Targeted Immunotherapy
A key area of interest lies in developing optimized treatment protocols using immunotherapeutic agents in combination with conventional chemotherapy.
Hematological Disorders
The investigator conducts research in chronic blood disorders, with particular emphasis on sickle cell disease and thalassemia. Their work encompasses both transfusion-dependent and non-transfusion-dependent cases.
- Blood Disorder Management
- Long-term Treatment Strategies
- Pediatric Hematology
The research focuses on developing sustained therapeutic approaches for patients across different age groups affected by inherited blood disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.